Experts Weigh in at FDA Meeting on Patient-Centric Drug Development

Drug Industry Daily
The FDA received a wide range of comments and questions Monday at a public meeting to receive comments on a discussion document on patient-focused drug development — an early draft for the agency’s planned series of guidances on the topic.

To View This Article:


Subscribe To Drug Industry Daily